OBJECTIVE: The aldosterone-to-renin ratio is widely used and is the recommended screening modality for primary aldosteronism by the Endocrine Society Guideline. However, studies on its diagnostic accuracy have been inconsistent, which is mainly because of methodological limitations. We set out to evaluate this diagnostic value by using a highly standardized study protocol, which is in line with the Endocrine Society Guideline recommendations regarding indications for screening, testing conditions and reference standards in daily clinical practice. METHODS: In this prospective study, 233 consecutive patients referred to the University Medical Center Utrecht with difficult-to-control hypertension were enrolled. In addition to aldosterone-to-renin ratio measurements, all patients underwent a saline infusion test as a reference standard. A plasma aldosterone concentration greater than 280 pmol/l after saline infusion was considered diagnostic for aldosteronism and the plasma renin activity was assessed to exclude patients with secondary aldosteronism from the final primary aldosteronism diagnosis. RESULTS: Correlation of the aldosterone-to-renin ratio (cut-off >5) with primary aldosteronism diagnosis showed 16 true positive, 29 false positive, 188 true negative and 0 false negative aldosterone-to-renin ratios, resulting in a sensitivity of 100% (CI 75.9-100), specificity of 86.7% (CI 81.2-90.7), positive-predictive value of 35.6% (CI 22.3-51.3) and negative-predictive value of 100% (CI 97.5-100.0). The corresponding area under the curve was 0.933 (CI 0.900-0.966). CONCLUSION: These findings show that the aldosterone-to-renin ratio is a good screening modality for primary aldosteronism and is without a high risk of missing a primary aldosteronism diagnosis whenever performed under well standardized conditions.
OBJECTIVE: The aldosterone-to-renin ratio is widely used and is the recommended screening modality for primary aldosteronism by the Endocrine Society Guideline. However, studies on its diagnostic accuracy have been inconsistent, which is mainly because of methodological limitations. We set out to evaluate this diagnostic value by using a highly standardized study protocol, which is in line with the Endocrine Society Guideline recommendations regarding indications for screening, testing conditions and reference standards in daily clinical practice. METHODS: In this prospective study, 233 consecutive patients referred to the University Medical Center Utrecht with difficult-to-control hypertension were enrolled. In addition to aldosterone-to-renin ratio measurements, all patients underwent a saline infusion test as a reference standard. A plasma aldosterone concentration greater than 280 pmol/l after saline infusion was considered diagnostic for aldosteronism and the plasma renin activity was assessed to exclude patients with secondary aldosteronism from the final primary aldosteronism diagnosis. RESULTS: Correlation of the aldosterone-to-renin ratio (cut-off >5) with primary aldosteronism diagnosis showed 16 true positive, 29 false positive, 188 true negative and 0 false negative aldosterone-to-renin ratios, resulting in a sensitivity of 100% (CI 75.9-100), specificity of 86.7% (CI 81.2-90.7), positive-predictive value of 35.6% (CI 22.3-51.3) and negative-predictive value of 100% (CI 97.5-100.0). The corresponding area under the curve was 0.933 (CI 0.900-0.966). CONCLUSION: These findings show that the aldosterone-to-renin ratio is a good screening modality for primary aldosteronism and is without a high risk of missing a primary aldosteronism diagnosis whenever performed under well standardized conditions.
Authors: Wessel M C M Vorselaars; Dirk-Jan van Beek; Diederik P D Suurd; Emily Postma; Wilko Spiering; Inne H M Borel Rinkes; Gerlof D Valk; Menno R Vriens Journal: World J Surg Date: 2020-06 Impact factor: 3.352
Authors: Graeme Eisenhofer; Max Kurlbaum; Mirko Peitzsch; Georgiana Constantinescu; Hanna Remde; Manuel Schulze; Denise Kaden; Lisa Marie Müller; Carmina T Fuss; Sonja Kunz; Sylwia Kołodziejczyk-Kruk; Sven Gruber; Aleksander Prejbisz; Felix Beuschlein; Tracy Ann Williams; Martin Reincke; Jacques W M Lenders; Martin Bidlingmaier Journal: J Clin Endocrinol Metab Date: 2022-04-19 Impact factor: 6.134
Authors: Monique E A M van Kleef; Frank L J Visseren; Jan Westerink; Michiel L Bots; Peter J Blankestijn; Yolanda van der Graaf; Wilko Spiering Journal: BMC Endocr Disord Date: 2020-04-29 Impact factor: 2.763
Authors: Stefan Pilz; Martin H Keppel; Christian Trummer; Verena Theiler-Schwetz; Marlene Pandis; Valentin Borzan; Matthias Pittrof; Barbara Obermayer-Pietsch; Martin R Grübler; Nicolas Verheyen; Vinzenz Stepan; Andreas Meinitzer; Jakob Voelkl; Winfried März; Andreas Tomaschitz Journal: J Endocr Soc Date: 2019-07-19
Authors: Gregory P Veldhuizen; Rawan M Alnazer; Abraham A Kroon; Peter W de Leeuw Journal: J Clin Hypertens (Greenwich) Date: 2020-12-27 Impact factor: 3.738